

Prior authorization requirements for high-level, definitive drug testing

Effective December 1, 2018, prior authorization (PA) requirements will change for high-level, definitive drug testing. Amerigroup STAR+PLUS MMP (Medicare-Medicaid Plan) will require PA for high-level, definitive drug testing for our members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage. **Noncompliance with new requirements may result in denied claims.**

PA requirements will be added to the following:

- G0482 — Drug test(s), definitive, utilizing 1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gas chromatography/mass spectrometry (GC/MS) (any type, single or tandem) and liquid chromatography/mass spectrometry (LC/MS) (any type, single or tandem and excluding immunoassays; e.g., immunoassays [IA]; enzyme immunoassay [EIA]; enzyme-linked immunosorbent assay [ELISA]; enzyme multiplied immunoassay technique [EMIT]; fluorescence polarization immunoassay [FPIA]; and enzymatic methods [e.g., alcohol dehydrogenase]); 2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength); and 3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es) including metabolite(s) if performed
- G0483 — Drug test(s), definitive, utilizing 1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays; e.g., IA; EIA; ELISA; EMIT; FPIA; and enzymatic methods [e.g., alcohol dehydrogenase]); 2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength); and 3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es) including metabolite(s) if performed.

To request PA, you may use one of the following methods:

- **Web:** <https://www.availity.com>
- **Fax:** 1-888-235-8468
- **Phone:** 1-855-878-1785

Not all PA requirements are listed here. PA requirements are available to contracted providers by accessing the provider self-service tool at <https://providers.amerigroup.com/TX>. Under *Provider Resources & Documents*, select **Quick Tools**, then **Precertification Lookup Tool**. Contracted and non-contracted providers may call Provider Services at 1-855-878-1785 for assistance with PA requirements.